Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRO1106
- Development stage
- Unknown
- Lead developer
- Genmab
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PRO1106 is an investigational antibody-drug conjugate (ADC) developed by ProfoundBio. It targets SLIT and NTRK-like protein 6 (SLITRK6) on tumor cells and delivers a cytotoxic payload that inhibits DNA topoisomerase I (TOP1). The drug is designed to selectively bind to SLITRK6-expressing cancer cells, internalize rapidly, and induce cell death through the inhibition of TOP1, which disrupts DNA replication in tumor cells. Preclinical data indicate robust cytotoxicity in SLITRK6-positive tumor models. Its primary indication is for the treatment of solid tumors[1][2][7].
02
Targets
SLITRK6 (SLIT and NTRK-like protein 6)
Beyond the preview
Go deeper on PRO1106.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRO1106.